Inspiration Healthcare PLC and Genedrive PLC launch test for risk of neonatal hearing loss


Inspiration Healthcare Group PLC (AIM:IHC) has launched a kit to diagnose newborns at risk of hearing loss from certain types of antibiotics.

AIM-listed Genedrive has developed the new kit, which will be distributed by Inspiration, to screen babies for the genetic variant inherited from the mother called MT-RNR1, which, if left undetected, can cause permanent and irreversible deafness.

Through this partnership, Inspiration has an exclusive agreement to distribute the kit in the UK and Ireland and the aim is to enable testing of all children receiving antibiotics upon admission to intensive care.

In the UK, around 90,000 babies are admitted to the NICU each year and around 80-85% of them receive antibiotics, he added.

Genedrive’s genetic test can be performed in less than 30 minutes, allowing alternative treatment decisions on antibiotics to be made within an hour of admission.

Inspiration Healthcare has the option to extend the agreement through its global sales network.

Neil Campbell, Managing Director of Inspiration, said, “We are delighted to be involved in this groundbreaking approach to treating MT-RNR1 with Genedrive.

“It fits perfectly with our experience in providing innovative solutions to improve outcomes for newborns.”


Comments are closed.